IBDEI0E1 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18795,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18795,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,18795,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,18795,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,18796,0)
 ;;=289.9^^117^1098^66
 ;;^UTILITY(U,$J,358.3,18796,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18796,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,18796,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,18796,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,18797,0)
 ;;=205.02^^117^1098^30
 ;;^UTILITY(U,$J,358.3,18797,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18797,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,18797,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18797,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,18798,0)
 ;;=205.12^^117^1098^16
 ;;^UTILITY(U,$J,358.3,18798,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18798,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,18798,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18798,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,18799,0)
 ;;=205.20^^117^1098^59
 ;;^UTILITY(U,$J,358.3,18799,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18799,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,18799,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,18799,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,18800,0)
 ;;=205.21^^117^1098^58
 ;;^UTILITY(U,$J,358.3,18800,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18800,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,18800,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,18800,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,18801,0)
 ;;=205.22^^117^1098^57
 ;;^UTILITY(U,$J,358.3,18801,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18801,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,18801,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18801,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,18802,0)
 ;;=205.30^^117^1098^35
 ;;^UTILITY(U,$J,358.3,18802,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18802,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,18802,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,18802,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,18803,0)
 ;;=205.31^^117^1098^34
 ;;^UTILITY(U,$J,358.3,18803,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18803,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,18803,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,18803,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,18804,0)
 ;;=205.32^^117^1098^33
 ;;^UTILITY(U,$J,358.3,18804,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18804,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,18804,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,18804,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,18805,0)
 ;;=205.80^^117^1098^44
 ;;^UTILITY(U,$J,358.3,18805,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18805,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,18805,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18805,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,18806,0)
 ;;=205.81^^117^1098^43
 ;;^UTILITY(U,$J,358.3,18806,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18806,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,18806,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18806,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,18807,0)
 ;;=205.82^^117^1098^42
 ;;^UTILITY(U,$J,358.3,18807,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18807,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,18807,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18807,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,18808,0)
 ;;=205.90^^117^1098^65
 ;;^UTILITY(U,$J,358.3,18808,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18808,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,18808,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,18808,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,18809,0)
 ;;=205.91^^117^1098^64
 ;;^UTILITY(U,$J,358.3,18809,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18809,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,18809,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,18809,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,18810,0)
 ;;=205.92^^117^1098^63
 ;;^UTILITY(U,$J,358.3,18810,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18810,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,18810,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18810,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,18811,0)
 ;;=206.00^^117^1098^6
 ;;^UTILITY(U,$J,358.3,18811,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18811,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,18811,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,18811,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,18812,0)
 ;;=206.01^^117^1098^5
 ;;^UTILITY(U,$J,358.3,18812,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18812,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,18812,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,18812,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,18813,0)
 ;;=206.02^^117^1098^4
 ;;^UTILITY(U,$J,358.3,18813,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18813,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,18813,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18813,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,18814,0)
 ;;=206.10^^117^1098^15
 ;;^UTILITY(U,$J,358.3,18814,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18814,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,18814,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,18814,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,18815,0)
 ;;=206.11^^117^1098^14
 ;;^UTILITY(U,$J,358.3,18815,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18815,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,18815,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,18815,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,18816,0)
 ;;=206.12^^117^1098^13
 ;;^UTILITY(U,$J,358.3,18816,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18816,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,18816,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18816,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,18817,0)
 ;;=206.20^^117^1098^55
 ;;^UTILITY(U,$J,358.3,18817,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18817,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,18817,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,18817,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,18818,0)
 ;;=206.21^^117^1098^54
 ;;^UTILITY(U,$J,358.3,18818,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18818,1,1,0)
 ;;=1^206.21
 ;;^UTILITY(U,$J,358.3,18818,1,8,0)
 ;;=8^Subacute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18818,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,18819,0)
 ;;=206.22^^117^1098^56
 ;;^UTILITY(U,$J,358.3,18819,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18819,1,1,0)
 ;;=1^206.22
 ;;^UTILITY(U,$J,358.3,18819,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,18819,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,18820,0)
 ;;=206.80^^117^1098^41
 ;;^UTILITY(U,$J,358.3,18820,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18820,1,1,0)
 ;;=1^206.80
 ;;^UTILITY(U,$J,358.3,18820,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remission
 ;;^UTILITY(U,$J,358.3,18820,2)
 ;;=^336864
 ;;^UTILITY(U,$J,358.3,18821,0)
 ;;=206.81^^117^1098^40
 ;;^UTILITY(U,$J,358.3,18821,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18821,1,1,0)
 ;;=1^206.81
 ;;^UTILITY(U,$J,358.3,18821,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remiss
 ;;^UTILITY(U,$J,358.3,18821,2)
 ;;=^267551
 ;;^UTILITY(U,$J,358.3,18822,0)
 ;;=206.82^^117^1098^39
 ;;^UTILITY(U,$J,358.3,18822,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18822,1,1,0)
 ;;=1^206.82
 ;;^UTILITY(U,$J,358.3,18822,1,8,0)
 ;;=8^Oth Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18822,2)
 ;;=^336479
 ;;^UTILITY(U,$J,358.3,18823,0)
 ;;=206.90^^117^1098^62
 ;;^UTILITY(U,$J,358.3,18823,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18823,1,1,0)
 ;;=1^206.90
 ;;^UTILITY(U,$J,358.3,18823,1,8,0)
 ;;=8^Unspec Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,18823,2)
 ;;=^336865
 ;;^UTILITY(U,$J,358.3,18824,0)
 ;;=206.91^^117^1098^61
 ;;^UTILITY(U,$J,358.3,18824,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18824,1,1,0)
 ;;=1^206.91
 ;;^UTILITY(U,$J,358.3,18824,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,18824,2)
 ;;=^267554
 ;;^UTILITY(U,$J,358.3,18825,0)
 ;;=206.92^^117^1098^60
 ;;^UTILITY(U,$J,358.3,18825,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18825,1,1,0)
 ;;=1^206.92
 ;;^UTILITY(U,$J,358.3,18825,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18825,2)
 ;;=^336480
 ;;^UTILITY(U,$J,358.3,18826,0)
 ;;=207.00^^117^1098^3
 ;;^UTILITY(U,$J,358.3,18826,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18826,1,1,0)
 ;;=1^207.00
 ;;^UTILITY(U,$J,358.3,18826,1,8,0)
 ;;=8^AC Eryth & Erythroleuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,18826,2)
 ;;=^336866
 ;;^UTILITY(U,$J,358.3,18827,0)
 ;;=207.01^^117^1098^1
 ;;^UTILITY(U,$J,358.3,18827,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18827,1,1,0)
 ;;=1^207.01
 ;;^UTILITY(U,$J,358.3,18827,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,18827,2)
 ;;=^267556
 ;;^UTILITY(U,$J,358.3,18828,0)
 ;;=207.02^^117^1098^2
 ;;^UTILITY(U,$J,358.3,18828,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18828,1,1,0)
 ;;=1^207.02
 ;;^UTILITY(U,$J,358.3,18828,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,18828,2)
 ;;=^336481
 ;;^UTILITY(U,$J,358.3,18829,0)
 ;;=207.10^^117^1098^9
 ;;^UTILITY(U,$J,358.3,18829,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18829,1,1,0)
 ;;=1^207.10
 ;;^UTILITY(U,$J,358.3,18829,1,8,0)
 ;;=8^Chr Erythremia w/o Remission
 ;;^UTILITY(U,$J,358.3,18829,2)
 ;;=^336867
 ;;^UTILITY(U,$J,358.3,18830,0)
 ;;=207.11^^117^1098^8
 ;;^UTILITY(U,$J,358.3,18830,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18830,1,1,0)
 ;;=1^207.11
 ;;^UTILITY(U,$J,358.3,18830,1,8,0)
 ;;=8^Chr Erythremia in Remission
 ;;^UTILITY(U,$J,358.3,18830,2)
 ;;=^267558
